Sitemap
-
Licensing and supervision
-
Brexit
- Mutual Recognition Procedure (MRP) and Decentralised Procedure (DCP)
- Centralised authorisation procedure
- Parallel import and parallel distribution
- Nationally authorised medicinal products
- Medical devices and Brexit
- Clinical trials
- Marketed products
- Compassionate use permits
- Questions and answers on Brexit
- Links
-
Licensing of medicines
- SPCs, package leaflets and labelling
- Marketing authorisation
- Receipt, acceptance and approval letters
-
Renewal of marketing authorisation
-
Safety features on medicinal products
- Changing the legal status of a human medicinal product
- Patented indications and substitution
-
Variations
-
Parallel import
- Deregistration
- Parallel distribution
- Naming of medicines
- Case statistics and order books
- Lists of authorised and deregistered medicines
- Medicines authorised with a summary of the risk management plan
- Educational materials for medicinal products
- Medicines under additional monitoring
- Authorisation procedures
-
Company authorisations and registrations
- Company authorisations
- Company registrations
- Manufacture of medicines and intermediates
- Registration as manufacturer, importer and distributor of active substances (APIs)
- Wholesale distribution
- Brokering of medicines
- Distribution of medicines outside pharmacies
- Medical gases
- Veterinary medicinal substances
- Euphoriant substances
- Radiopharmaceuticals
- Toxicological and pharmacological trials
- Supervision and inspection
- Clinical trials
- How to evaluate evidence of the efficacy of medicines
-
Evaluation of reviews
-
Report suspected illegal activities
- Falsified medicines
- Compassionate use
- Medicine or not
- Export certificates
- Fees
- Name/address changes
- Relationships
- Financial support
- Medicinal Products Committee
- Publications
-
Brexit
-
Side effects and product information
-
Side effects of medicines
- Report a side effect
- Registration and monitoring
- EudraVigilance
- Companies' reporting of side effects
- Interactive Adverse Drug Reaction overviews
- Stricter reporting requirements
- Compensation for pharmaceutical injuries
-
EU Pharmacovigilance Risk Assessment Commitee
- Childhood vaccines
- Pharmacovigilance and inspections
-
Network for the Prevention of Medication Errors
-
Danish Pharmacovigilance Update
- Publications
- Additional monitoring
- News on pharmacovigilance
- Biological and biosimilar medicinal products
- Safety updates
- Direct Healthcare Professional Communication
-
Adverse events
-
Drug interaction
-
Pharmacovigilance Council
- Find medicines
- Publications
-
Side effects of medicines
-
Reimbursement and prices
- General reimbursement
- Individual reimbursement
- Calculate reimbursement
-
Medicines bought in another EU/EEA country
- Reimbursement Committee
- Prices of medicines
- Product numbers
- Central Reimbursement Register
- Reimbursable nutritional products
- Publications
-
Pharmacies and sale of medicines
- Pharmacies
- Sale outside pharmacies
- Over-the-counter medicines
-
Substitution
- Medicines imported from abroad
- Buying and selling medicines online
- Sale of medicines or food supplements online
- Doctors buying medicines for use in their own practices
-
Report suspected illegal sale of medicines
- Prescriptions from another country
- Publications
-
Medical devices
- New Tech – new technological possibilities and medical devices
- Patient safety and safe medical devices
-
Development of medical devices
- CE marking
- Incident reporting
- Notified bodies
-
Registration and marketing
- Manufacturers of medical devices
-
Manufacturers of in vitro diagnostic devices (IVD)
- Distributors and importers
-
Changes in company information or information about marketed devices
-
Deregistration
-
Specialised stores
- Marketing and advertising
- Collaboration with healthcare professionals
- Language requirement
- Clinical investigations
-
Certificates of Free Sale
- Legislation and guidance
- Publications
-
Special product areas
- Veterinary medicines
- Natural medicinal products and vitamin and mineral products
- Euphoriant substances
-
Medical gases
- Radiopharmaceuticals
- Medicines affecting the ability to drive
-
Medicinal cannabis
-
Citizens
-
What is medicinal cannabis?
- Medicinal cannabis pilot programme
- Graphical overview of the medicinal cannabis pilot programme
- Prices of cannabis products in the pilot programme
-
Questions and answers on medicinal cannabis
- Proprietary pharmacists' and doctors' relationships with companies
- Side effects and safety of medicinal cannabis
- Change of the THC limit as of 1 July 2018
- Reimbursement of medicinal cannabis of the pilot programme effective as of 1 January 2019
-
What is medicinal cannabis?
- Healthcare professionals
-
Companies
-
Pilot programme
- List of admitted cannabis products
- Admission of products to the medicinal cannabis pilot programme
- Authorisation to produce cannabis intermediate products
- Certificates
- Authorisation to produce cannabis bulk
- Rules about relationships to companies
- Ban on advertising
- Record-keeping and destruction of medicinal cannabis
- Classification of CBD products
- Cultivation agents
- Development scheme
-
Pilot programme
-
Citizens
-
About us
- Mission, vision and strategy
- Contact
-
Whistleblowing scheme of the Danish Medicines Agency
- Management of conflicts of interest
- Transparency in the Danish Medicines Agency
- Data protection policy
- Targets and tasks
- Activities in the EU and the rest of the world
- Jobs
- Digital services
- About this site
- Design
-
Campaigns
- Copyright
- Cookies
- Publications
- Sitemap
- Publications